Literature DB >> 29387248

Downregulated SOX9 mediated by miR-206 promoted cell apoptosis in Legg-Calvé-Perthes disease.

Junzhong Luo1, Jiuhui Han1, Yazhou Li1, Yuchang Liu1.   

Abstract

Legg-Calvé-Perthes disease (LCPD) commonly onsets in adolescents, and threatens their health. However, the potential mechanism underlying LCPD remains unclear. MicroRNA (miR)-206 and SRY-box 9 (SOX9) serve an important role in chondrocytes; however, their role in LCPD remains ambiguous. In the present study, whether miR-206 and SOX9 mediated cell apoptosis in dexamethasone (DEX)-induced LCPD was investigated. The chondrocytes of the LCPD and normal control group were isolated from clinical tissues. Reverse transcription-quantitative polymerase chain reaction was used to evaluate the expression of miR-206 and SOX9 mRNA. Western blotting was used to measure the protein level of SOX9. A combination of Annexin V-fluorescein isothiocyanate flow cytometry was used to assess cell apoptosis. The association between miR-206 and SOX9 was detected using a luciferase reporter assay. miR-206 was overexpressed while SOX9 was downregulated in chondrocytes treated with DEX obtained from patients with LCPD. miR-206 targeted SOX9 to regulate its expression. Overexpression of miR-206 promoted cell apoptosis in TC28, while it was reversed by SOX9 overexpression. TC28 cells pretreated with DEX significantly promoted cell apoptosis, while cells transfected with miR-206 inhibitor significantly reversed the effect; however, downregulated SOX9 abolished the effects of miR-206 inhibitor. SOX9 mediated by miR-206 possibly contributed to the pathogenesis of LCPD. The results of the present study suggest that miR-206 and SOX9 function as important therapeutic targets for the future of clinical therapy.

Entities:  

Keywords:  Legg-Calvé-Perthes disease; SOX9; apoptosis; dexamethasone; miR-206

Year:  2017        PMID: 29387248      PMCID: PMC5768063          DOI: 10.3892/ol.2017.7373

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  20 in total

1.  Direct rAAV SOX9 administration for durable articular cartilage repair with delayed terminal differentiation and hypertrophy in vivo.

Authors:  Magali Cucchiarini; Patrick Orth; Henning Madry
Journal:  J Mol Med (Berl)       Date:  2012-11-13       Impact factor: 4.599

2.  Irx3 and Bmp2 regulate mouse mesenchymal cell chondrogenic differentiation in both a Sox9-dependent and -independent manner.

Authors:  Yoshihiro Tamamura; Kenichi Katsube; Hisashi Mera; Maki Itokazu; Shigeyuki Wakitani
Journal:  J Cell Physiol       Date:  2017-04-10       Impact factor: 6.384

3.  Impaired osteogenic differentiation associated with connexin43/microRNA-206 in steroid-induced avascular necrosis of the femoral head.

Authors:  Gang Liu; Gaobin Luo; Zhandong Bo; Xiaonan Liang; Jie Huang; Donghui Li
Journal:  Exp Mol Pathol       Date:  2016-07-21       Impact factor: 3.362

4.  miR-206 is down-regulated in breast cancer and inhibits cell proliferation through the up-regulation of cyclinD2.

Authors:  Jing Zhou; Ye Tian; Juan Li; Binbin Lu; Ming Sun; Yanfen Zou; Rong Kong; Yanhong Luo; Yongguo Shi; Keming Wang; Guozhong Ji
Journal:  Biochem Biophys Res Commun       Date:  2013-03-01       Impact factor: 3.575

5.  Clarithromycin and dexamethasone show similar anti-inflammatory effects on distinct phenotypic chronic rhinosinusitis: an explant model study.

Authors:  Ming Zeng; Zhi-Yong Li; Jin Ma; Ping-Ping Cao; Heng Wang; Yong-Hua Cui; Zheng Liu
Journal:  BMC Immunol       Date:  2015-06-06       Impact factor: 3.615

6.  Dexamethasone in osteogenic medium strongly induces adipocyte differentiation of mouse bone marrow stromal cells and increases osteoblast differentiation.

Authors:  Olfa Ghali; Odile Broux; Guillaume Falgayrac; Nathalie Haren; Johannes P T M van Leeuwen; Guillaume Penel; Pierre Hardouin; Christophe Chauveau
Journal:  BMC Cell Biol       Date:  2015-03-13       Impact factor: 4.241

7.  Enoxaparin prevents steroid-related avascular necrosis of the femoral head.

Authors:  Rainer Beckmann; Hayfaa Shaheen; Nisreen Kweider; Alireza Ghassemi; Athanassios Fragoulis; Benita Hermanns-Sachweh; Thomas Pufe; Mamed Kadyrov; Wolf Drescher
Journal:  ScientificWorldJournal       Date:  2014-07-02

8.  MicroRNA-494 inhibits cell proliferation and invasion of chondrosarcoma cells in vivo and in vitro by directly targeting SOX9.

Authors:  Jingyuan Li; Lijuan Wang; Zongzhi Liu; Chao Zu; Fanfan Xing; Pei Yang; Yongkang Yang; Xiaoqian Dang; Kunzheng Wang
Journal:  Oncotarget       Date:  2015-09-22

9.  Oncogenic miRNA-182-5p targets Smad4 and RECK in human bladder cancer.

Authors:  Hiroshi Hirata; Koji Ueno; Varahram Shahryari; Yuichiro Tanaka; Z Laura Tabatabai; Yuji Hinoda; Rajvir Dahiya
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

10.  Serum microRNA expression as an early marker for breast cancer risk in prospectively collected samples from the Sister Study cohort.

Authors:  Ashley C Godfrey; Zongli Xu; Clarice R Weinberg; Robert C Getts; Paul A Wade; Lisa A DeRoo; Dale P Sandler; Jack A Taylor
Journal:  Breast Cancer Res       Date:  2013-05-24       Impact factor: 6.466

View more
  2 in total

1.  Exploring dysregulated miRNAs in cryptorchidism: a systematic review.

Authors:  Hongshuai Jia; Chunsheng Hao
Journal:  J Int Med Res       Date:  2021-03       Impact factor: 1.671

2.  Altered miRNA profile in testis of post-cryptorchidopexy patients with non-obstructive azoospermia.

Authors:  Dongdong Tang; Zhenyu Huang; Xiaojin He; Huan Wu; Dangwei Peng; Li Zhang; Xiansheng Zhang
Journal:  Reprod Biol Endocrinol       Date:  2018-08-13       Impact factor: 5.211

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.